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Electron microscopyThe appearance of drug-resistant strains ofMycobacterium tuberculosis (Mtb) poses a great challenge to the de-
velopment of novel treatment programmes to combat tuberculosis. Since innovative nanotechnologiesmight al-
leviate the limitations of current therapies, we have designed a new nanoformulation for use as an anti-TB drug
delivery system. It consists of incorporatingmycobacterial cell wall mycolic acids (MA) as targeting ligands into a
drug-encapsulating Poly DL-lactic-co-glycolic acid polymer (PLGA), via a double emulsion solvent evaporation
technique. Bonemarrow-derivedmousemacrophages, either uninfected or infectedwith differentmycobacterial
strains (Mycobacterium avium,Mycobacterium bovis BCG orMtb), were exposed to encapsulated isoniazid-PLGA
nanoparticles (NPs) using MA as a targeting ligand. The fate of the NPs was monitored by electron microscopy.
Our study showed that i) the inclusion of MA in the nanoformulations resulted in their expression on the
outer surface and a signiﬁcant increase in phagocytic uptake of the NPs; ii) nanoparticle-containing phagosomes
were rapidly processed into phagolysosomes, whether MA had been included or not; and iii) nanoparticle-
containing phagolysosomes did not fuse with non-matured mycobacterium-containing phagosomes, but fusion
events with mycobacterium-containing phagolysosomes were clearly observed.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Tuberculosis (TB) is mainly a burden of the developing world, but
has also a great impact globally with an estimated annual 8.6 million
incident cases. It also ranks as the second leading cause of death from
a communicable disease (second to Acquired Immunodeﬁciency Syn-
drome (AIDS)) with 1.3 million deaths reported in 2012 [1]. TB-AIDS
can be classiﬁed as a new combination disease, since Human Immuno-
deﬁciency Virus/Mycobacterium tuberculosis (HIV/Mtb) co-infection
has become such a frequent occurrence in third world countries. In
comparison to TB alone, TB/AIDS patients have severely reduced surviv-
al times, are more challenging to diagnose [2] and may exhibit some-
times fatal immune reconstitution inﬂammatory syndrome (IRIS)
when subjected to anti-retroviral therapy [3]. Standard ﬁrst line chemo-
therapy is not effective for individuals that are infected withmulti-drugManufacturing, Meiring Nauderesistant (MDR) Mtb strains and there is practically no cure for
extensively-drug resistant (XDR) ones. Failure to complete the lengthy
drug regimens allows the pathogens to become resistant especially to
the two ﬁrst line drugs, isoniazid (INH) and rifampicin (RIF). This is in-
creasingly evident in persons who have been previously treated for TB
[4]. It is now imperative to discover new chemotherapies against this
mycobacterium as well as to enhance the efﬁcacy of existing drugs to
combat MDR and XDR forms [5]. In addition, it is important to ﬁnd
new technologies for targeting chemotherapeutic agents and toxic
host cell effector molecules through the lipid-rich wax-like mycobacte-
rial cell wall [6].
Innovative nanotechnologies have been designed and tested tomeet
the challenges posed by the pathogen and poor drug efﬁcacy. Their
potential to improve compliance, efﬁcacy and affordability of therapy
makes them especially suited for addressing the treatment of TB and
AIDS. Nanomedicine (the medical application of nanotechnology)
has the potential to improve bioavailability, reduce toxic side effects, re-
duce drug–drug interactions and overcome drug resistance. Further-
more, nanoformulations can improve drug solubility and facilitate
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Nano drug delivery systems are generally prepared with natural or syn-
thetic compounds (i.e. polymers and lipids) using various techniques to
yield particles ranging in size between 10 and 1000 nm in diameter [7].
Many groups have used poly DL, lactic–co-glycolic acid (PLGA) as the
polymeric encapsulating material because it is non-immunogenic, bio-
degradable and has the capacity to encapsulate hydrophobic and hydro-
philic agents [8]. PLGA was also shown to be selectively taken up into
macrophages and dendritic cells [9], the main targets for infection
with Mtb [10]. In addition, the cytotoxicity of PLGA was evaluated
in vitro and in vivo and no signiﬁcant adverse effects were noted [11].
Nanoencapsulation of drugs for delivery provides an opportunity to
incorporate targeting strategies to further enhance drug efﬁciency and
limit systemic toxic side-effects to the patient. By functionalizing the
surface of the particles with a targeting ligand, higher bioavailability
could be generated at the site of infection and therefore the dose and
side effects of the drug are minimized [12]. An effective targeting strat-
egy will impact positively on drug delivery to the site of infection, may
direct the trafﬁcking of the drugs into organelles in which pathogens
are harboured and may improve the release and longevity of the active
drug. A comprehensive review of the recent advances in targeting with
drug carrier designs for TB was done by Dube and colleagues [13].
The mycobacterial cell wall is composed of many compounds that
could serve as targeting ligands. Among these, mycolic acids (MA) are
promising candidates because they are the dominant lipids found in
the outer cell wall envelope of Mycobacterium species [14]. MA are
long 2-alkyl 3-hydroxyl fatty acids and in Mtb, MA consist mainly of
alpha-, keto- and methoxy classes, typically 70–90 carbon atoms in
length, each containing mixtures of homologs of varying chain lengths
and, in some cases different stereochemistry around functional groups
in the main (mero-) chain [15]. The various subtypes of MA have been
shown to play a major role in the virulence of the pathogen [6,16]. MA
fromMtb have interesting biological activities, including foam cell for-
mation and immune steering towards Th1 cellular responses [17–19],
as well as cholesteroid like properties [20,21]. MA was also shown
to be immunogenic. When presented by CD1b molecules on den-
dritic cells, proliferation of human CD4−, CD8− (double negative)
T-lymphocytes occurs [22,23]. In addition, anti-MA antibodies are
found in human TB-positive patient serum [24]. Mycobacterial MA has
never been tested as a ligand for improving nanoencapsulated anti-
tuberculosis (anti-TB) drug targeting. An attractive hypothesis would
be that the MA present on the external surface of the NPs may interact
with anti-MA antibodies in the vicinity of the sites of infection to cause a
localised immune complex that may enhance uptake of the NPs in the
infected and surrounding uninfected macrophages. MA could also tar-
get cholesterol present in the plasmamembrane of uninfected or infect-
ed macrophages [25,26] and, more interestingly, in the membrane of
phagosomes in which pathogenic mycobacteria are harboured [27], by
means of its attraction to cholesterol [20,21,28].
To understand whether or how this happens demands an intricate
knowledge of the cellular and molecular mechanisms of survival of the
pathogen of interest andmore precisely how the pathogen uses or diverts
the cellularmachinery to its advantage. It iswell known that the preferred
site of residence of pathogenic mycobacteria in the host macrophage is
the immature phagosome [29] which is unable to fuse with lysosomes
[30,31]. However, mycobacteria internalized in clumps, a frequent event
in the case ofMtb, are unable to block phagosome maturation [32–35].
In this case, phagosomes mature and fuse with lysosomes to become
phagolysosomes. Interestingly, mycobacteria do not die in this cytolytic
environment from which they are eventually rescued to reside in
phagosomes that no longer fusewith lysosomes [29]. Severalmore recent
studies also indicate that Mtb, but not Mycobacterim bovis BCG or
Mycobacterium avium, may evade phagosomes to survive in the host
cell cytosol immediately prior to host cell lysis [36–39].
The subcellular localisation of PLGA particles in cells is a ﬁeld that
has hitherto yielded conﬂicting results over the past decade. On theone hand, PLGA particles were suggested to be able to escape the
endomembrane compartments into the cytosol of a smooth muscle
cell line within minutes after phagocytic uptake [12,40]. More groups
supported this interpretation for different cell types, including macro-
phages [41–43]. On the other hand, the PLGA particles were suggested
to remain within the phagolysosomal compartment for several days
[44–46]. Another issue is the ability for PLGA particles to reach the com-
partment in which mycobacteria reside. One group suggested this pos-
sibility [47], but others could not demonstrate it [10,45].
Previous efforts to demonstrate a potential beneﬁt of MA as a drug-
targeting ligand utilized ﬂuorescently labelled MA in a human myelo-
monocytic cell line by means of confocal laser-scanning ﬂuorescence
microscopy (CLSM) [48]. The ﬂuorescently labelled MA in NPs were
shown to be actively taken up by the cell lines. In the present work,
we assess the use ofmycobacterial MA as a ligand for nanoencapsulated
anti-Mtb drug targeting on the uptake and intracellular fate of the NPs
by electron microscopy (EM) methods. It is important to recall that
EM is the only technique that can combine sensitive protein detection
methods with detailed information on the ultrastructure and interac-
tion of mycobacteria and cellular compartments. A nanoformulation of
incorporated MA in a PLGA polymer was achieved via the double emul-
sion solvent evaporation technique. INH was incorporated as the anti-
TB drug model in our PLGA particles due to its known cytotoxicity as a
ﬁrst line drug against actively replicatingMtb. We chose to infect mouse
bone marrow-derived macrophages (BMDM) with eitherMtb, M. bovis
BCG or M. avium. Six days later, cells were exposed to the synthesized
NPs, with or without the potential targeting ligand MA. We show that
MA enhanced the uptake of NPs into mycobacterium-infected macro-
phages. Newly formed nanoparticle-containing phagosomes were
processed into phagolysosomes within hours. Such phagolysosomes
were able to fuse with and deliver their contents to mycobacterium-
containing phagolysosomes but not to immature phagosomes. We now
clearly demonstrate that NPs do co-localise with mycobacteria in the
phagolysosomal compartments.
2. Materials and methods
2.1. Chemicals and reagents
Dimethyl sulfoxide, Isoniazid (99%), mycobacteria-derived MA,
PLGA 50:50 (Mw: 45,000–75,000), Polyvinyl alcohol MW: 13,000–
2,3000 partially hydrolysed (87–89%), Sodium dodecyl sulphate, Triton
X-100, Trypan blue, Basic fuchsin, Dulbecco's modiﬁed Eagle's medium
(DMEM), Tyloxapol and Glutaraldehyde grade I (EM grade) were
purchased from Sigma-Aldrich Chemical Co., (St Louis, MO, USA). Foetal
bovine serum (FBS) was from Biowest (Nuaillé, France), phosphate-
buffered saline (PBS) was from GIBCO (distributed by Invitrogen,
Villebonsur Yvette, France), and osmium tetroxide and Spurr resin
were from Electron Microscopy Sciences (distributed by Euromedex,
Mundolsheim, France). Middlebrook 7H9, 7H10 agar and Oleic acid-
albumin-dextrose-catalase (OADC) were from Difco Inc. (Detroit, MI,
USA). Bovine serum albumin conjugated to gold particles (BSA-Au)
waspurchased from theUtrecht University School ofMedicine (Utrecht,
The Netherlands).
2.2. Preparation of NPs
The double emulsion solvent evaporation freeze drying technique
was used as previously described with modiﬁcations [49]. PLGA 50:50
(MW: 45,000–75,000) was dissolved in 6 ml of dichloromethane
(DCM) at a concentration of 1.25% weight/volume (w/v). For particles
containing MA, isolated MA fromMtb (2 mg, 1.7 μmol) was dissolved
in 2 ml DCM and added while stirring. For the ﬁrst water-in-oil (w/o)
emulsion, 2 ml of aqueous PBS, pH 7.4, was added to the mixture and
homogenized at 5000 rpm for 3 min in a bench-top homogenizer at
4 °C. For NPs containing INH, INH (100 mg, 729 μmol) was dissolved
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quently transferred to an aqueous stabilizer solution of 2% (w/v) polyvi-
nyl alcohol. The second water-in-oil-in-water (w/o/w) emulsion was
formed by homogenization at 8000 rpm for 7 min, then stirred at
500 rpm overnight at atmospheric pressure and room temperature to
evaporate the organic solvent. The PLGA NPs were recovered by centri-
fugation at 845 and 33,902 rcf respectively for 15 min. The resulting
particles were dried by lyophilization in a Virtis Benchtop freeze dryer.
2.3. Nanoparticle characterisation
NPs collected after lyophilizationwere subjected to size and size dis-
tribution (polydispersity index) measurements by means of dynamic
light scattering as well as surface potential measurements by means of
laser doppler electrophoresis using a Zetasizer NanoZS instrument
(Malvern Instruments ltd. UK). NPs were also deposited onto alumini-
um stubs and coated with carbon in a glow-discharge apparatus to
examine their surface morphology by scanning electron microscopy
(SEM).
2.4. Quantiﬁcation of INH and MA within NPs
Quantiﬁcation of the INH encapsulated in theNPswas performed via
the direct method. Lyophilized NPs (10.0 mg) were suspended in 10ml
0.05 M NaOH and kept at room temperature (RT) overnight with con-
tinuous agitation. The samples were then neutralised with 0.1 M HCl
and analyzed via UV spectrometry at 260 nm [50].
Carbolfuchsin dyewas used to quantify the amount ofMA present in
the NPs [51]. The MA-containing NPs (20.0 mg) were dissolved in chlo-
roform (10 ml) and stirred overnight. Hexane was added to precipitate
the PLGA, and stirred vigorously for an hour. The precipitate was recov-
ered by ﬁltration through a 0.45 μm organic solvent resistant ﬁlter (Pall
Acrodisk) and washed two to three times with hexane. The hexane
extract was evaporated with nitrogen gas. The MA left in the vial was
re-dissolved in hexane (1 ml) followed by the addition of an equal
amount of carbolfuchsin dye. The absorbance of the hexane layer was
measured at 492 nm in an absorbance plate reader and a standard
curve was compiled.
2.5. Immuno detection of MA on particle surfaces
The presence ofMA on the surfacewas conﬁrmed by Enzyme-linked
immunosorbent assay (ELISA). Preparation of the ELISA plateswas done
as previously describedwithmodiﬁcations [28,52,53].Where liposomes
were used in the inhibition of serum anti-MA antibodies in literature
(75 μg MA/1 μl of serum), we used MA-NPs (2 μg MA/1 μl of serum).
MA for coating of the ELISA plates was prepared by dissolving the lipid
in hexane (3 μg/50 μl), vortexing for one minute, heating at ~85 ° C for
1min and left to stand at room temperature for 15min. Hexanewithout
MA served as coating control. The ELISA plates were coatedwith theMA
at 50 μl per well using a Hamilton syringe. Plates were stored in a plastic
bag at 4 °C overnight. The coated plates were blocked with 0.5% Casein/
PBS pH7.4 (400 μl/well) at RT. After 2 h, the blocking bufferwas aspirat-
ed and serum (1:20 dilution in 0.5% Casein/PBS, pH7.4) was added to
the plate (50 μl/well). Before the TB positive and negative human sera
were added to the wells, the serum was incubated for 1 h with PLGA
NPs with or without MA (2 mg/ml). Human sera used for analysis of
NPs were from a TB-positive patient serum and a healthy control, both
collected by Anton Stoltz of the Department of Internal Medicine (Infec-
tious Diseases), Faculty of Health Sciences, University of Pretoria and
were approved by the University Ethics Committee (159/2011 of 1 Sep-
tember 2011). Sampleswere centrifuged to remove particulatematerial
and the supernatantwas added to the plates (50 μl/well). After 1 h of in-
cubation, the wells were washed three times with a Well Wash4 ELISA
washer (Labsystems). The wells were then exposed to goat anti-human
Immunoglobulin G (H + L) peroxidase conjugate (50 μl/well) for30 min. at RT. After the incubation the wells were washed three times
with Casein/PBS, then incubated at RT with 50 μl per well of the sub-
strate solution consisting of 10 mg of OPD plus 8 mg of Urea–H2O2 in
10 ml of citrate buffer to develop the peroxidase activity. After 30 min,
the platewas readwith a SLT 340 ATC photometer at 450 nmwith a ref-
erence ﬁlter at 690 nm. Background binding of the serum to the plate
was corrected for by subtracting the average binding signal of serum
to MA from that registered for the hexane coated wells. Statistical com-
parisons of ELISA results were performed using the student t-test at a
conﬁdence level of 95%.
2.6. Mycobacteria
Three different mycobacterial strains were used: i) M. avium. The
transparent colony variant TMC 724 (serovar 2) was prepared as earlier
described [32]. Brieﬂy, mycobacteria of a ﬁrst passage were expanded
after isolation from the liver of C57BL/6 mice infected 6–8 weeks previ-
ously. Mycobacteria used for experiments were always of the ﬁrst
passage grown on Middlebrook 7H10 agar plates, supplemented with
0.5% Tween 80, 0.2% glycerol and 10% OADC; ii) M. bovis BCG Pasteur
1173P2 was grown in Sauton's medium containing 0.05% tyloxapol;
iii) Mtb H37Rv was grown in Middlebrook 7H9 supplemented with
0.5% Tween 80, 0.2% glycerol and 10% OADC. For all three strains, ali-
quots of bacterial suspensions were concentrated in Middlebrook 7H9
medium devoid of Tween and stored at−80 °C. When required, frozen
sampleswere quickly thawed, vortexed and adjusted to the desired titre
in complete cell culture medium. At least 90% of themycobacteria were
morphologically intact and viable at this stage.
2.7. Cell culturing and phagocytic uptake
Bone marrow cells were isolated from femurs of 6- to 8-week-old
C57BL/6 female mice and seeded onto tissue culture dishes (Falcon,
Becton Dickinson Labware, Meylan, France) of 35 mm in diameter
(4 × 105 cells per dish) or on 24-well tissue culture plates (1 × 105
perwell). The culturemediumwasDulbecco'smodiﬁedEagle'smedium
(DMEM)with high glucose (1 g/L) and high carbonate (3.7 g/L) concen-
trations supplemented with 10% heat-inactivated foetal bovine serum
(FBS), 10% L-cell conditioned medium (a source of CSF-1), and 2 mM
L-glutamine. At 5 days after seeding, the adherent cells were washed
twice with DMEM and re-fed with complete medium. Medium was
then renewed on day 6. No antibiotics were added. Seven-day-old mac-
rophages were infected for 4 h at 37 °C with eitherM. avium at a Multi-
plicity of Infection (MOI) of 20, M. bovis BCG at a MOI of 5, orMtb at a
MOI of 2. Infected cells were washed in four changes of ice-cold PBS to
eliminate non-ingested bacteria, and further incubated in complete
medium devoid of antibiotics.
2.8. Treatment with NPs and chase in NP-free medium
After active replication of mycobacteria for 6 days, infected cells
were exposed to INH-encapsulated PLGA NPs (0.1 mg per ml of
medium), with or without the targeting ligand, MA, for 2–4 h. Cells
were washed gently with three successive changes of DMEM and re-
incubated in complete medium devoid of NPs. At selected time points
post-treatment (0–12 days), cells were ﬁxed and processed for EM as
described below. Cells remained 98% viable for the entire duration of
the experiment, irrespective of post-infection treatment (data not
shown).
2.9. Labelling of lysosomes with BSA-gold
To label lysosomes,M. bovis BCG-infected macrophages were rinsed
with serum-free medium and incubated for 30 min at 37 °Cwith colloi-
dal gold particles of 10 nm in diameter conjugated with bovine serum
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three timeswith serum-freemedium and further incubated in complete
medium devoid of BSA-Au for 2 h at 37 °C. BSA-Au-treated cells were
then exposed to NPs as described above. At selected time points during
the treatment or the chase period, cells were ﬁxed and processed for
EM. Nanoparticle-containing phagosomes were examined for the pres-
ence or absence of BSA-Au.
2.10. Processing for conventional EM
Cells were ﬁxed for 1 h at RT with 2.5% glutaraldehyde in 0.1 M Na-
cacodylate buffer, pH 7.2, containing 0.1 M sucrose, 5 mM CaCl2 and
5 mM MgCl2. After this, they were washed with complete cacodylate
buffer, and post-ﬁxed for 1 h at RT with 1% osmium tetroxide in the
same buffer, but devoid of sucrose. Cells were then washed with buffer,
scraped off the dishes, concentrated in 2% agar in cacodylate buffer and
treated for 1 h at RT with 1% uranyl acetate in 30% methanol. Samples
were dehydrated in a graded series of ethanol and embedded in Spurr
resin. Thin sections (70 nm-thick) were stained with 1% uranyl acetate
in distilled water and then with lead citrate.
2.11. Quantiﬁcations
At the time points indicated, 100 to 200 different cell proﬁles were
examined under the EM to determine the number of NPs per cell proﬁle.
Nanoparticle-containing cell proﬁles were then examined to determine
the percentage of NPs enclosed in phagolysosomes. Cells were exam-
ined at random and care was taken to avoid serial sections.
3. Results
3.1. Production and characterisation of NPs
The freeze dried particles, recovered after the encapsulation of INH
and MA by the double emulsion evaporation technique, were used in
all experiments without further puriﬁcation. The physical characteris-
tics of theNPs used in the present study are summarized in Table 1. Dur-
ing themanufacture both large (800–900 nm) and small (220–250 nm)
particles were formed. Because of the bimodal size distribution nature
of the sample the two fractions were separated by varying the centrifu-
gal force, with the larger particles sedimenting at relatively low g-forces
as compared to smaller particles that needed relatively high g-forces.
Yield for the particles with or without the inclusion of MA was similar.
Collected large particles represented 32% whereas the small particles
represented 10%. The production yield of the encapsulation process
was 42% of particles over the initial solid mass of the reactants. The dif-
ferent NPs were next observed under a SEM. Irrespective of size, the
particles were mostly spherical and their surface was generally smooth
and uniform (Fig. 1A–D). We observed that the smaller particles had a
higher propensity for clumping than the larger ones.
The percentage of encapsulation of the hydrophilic INH was always
greater in the particles containing MA (Table 1). This could imply that
the addition of MA as a targeting ligand could simultaneously enhance
drug loading, and thus the amount that is transferred to infected
macrophages. The hydrophobic nature of MA might assist in theTable 1
Physical characteristics of NPs prepared by the solvent evaporation freeze drying method.
Preparation Average particle size (nm) Poly dispersity i
PLGA/INH 890 (±153) 0.4 (±0.1)
PLGA/INH/MA 929 (±197) 0.5 (±0.2)
PLGA/INH 254 (±33) 0.2 (±0.1)
PLGA/INH/MA 253 (±57) 0.2 (±0.1)
The (±) indicates the standard deviation (n = 3).reinforcement of the shell around the core containing INH, hence
preventing the INH to leak during the particle preparation process.
The degree of exposure of the MA on the surface of the NPs was inves-
tigated for the large and small NPs by probing them with antibodies
present in TB positive patient serum by means of an inhibition ELISA.
When MA is exposed on the NPs' surface after incorporation, the MA-
NPs will be able to form antibody complexes in solution preventing
much of the anti-MA antibodies in human patient serum to bind to
immobilized MA on the ELISA plate. This manifested as a reduced
ELISA signal (Fig. 1E) when NPs with or without MA were compared
in this assay, thus conﬁrming that the PLGA particles display MA as a
targeting ligand on the surface.
3.2. Inclusion of mycobacterial cell wall MA into PLGA enhances phagocytic
uptake of NPs by macrophages
MA are considered to be one of the major virulence factors of path-
ogenic mycobacteria. Given their location in the outermost layer of the
cell wall, and their ability to bind cholesterol, we investigated whether
their inclusion into PLGAwould affect phagocytic uptake of NPs bymac-
rophages. For this, BMDM were infected with either Mtb, M. avium or
M. bovis BCG and left to incubate for 6 days. The cells were then exposed
to PLGA or PLGA/MA particles for 2 h, ﬁxed and processed for electron
microscopy.
Qualitative aspects of NP-containing cell proﬁlemorphology showed
that cells contained signiﬁcantlymore NPs whenMA had been included
into PLGA (Fig. 2A vs B). Quantitative evaluations showed that 53% of
the cell proﬁles displayed at least one NP when cells had been exposed
to PLGA NPs vs 80% of the cell proﬁles after exposure to PLGA/MA. Eval-
uation of the average amount of NPs per cell proﬁle showed even clearer
differences with a 3 to 4-fold increase when MA was included into the
PLGA particles (with MA: 5.4+/−0.2 NPs; without MA: 1.5+/−0.4
NPs). The histogram distribution clearly showed that after exposure to
PLGA NPs for 2 h, more than 70% of the cell proﬁles displayed either
no or only one NPs. In contrast, when MA was included into PLGA,
about 70% of the cell proﬁles displayed 2 or more NPs (Fig. 2C).
These data demonstrated that inclusion of MA into PLGA induced a
signiﬁcantly higher phagocytic uptake of NPs by infected macrophages
and, in turn, an increase in the amount of NPs that could potentially
transfer active drugs to mycobacterium-containing phagosomes.
3.3. NPs with or without MA are located in phagolysosomes
It is of utmost importance to delineate the exact location of NPs
within cells as this will profoundly affect drug transfer to the
compartment(s) in which pathogenic mycobacteria reside. Whether
they rapidly evade into the cytosol [12,40] or remain enclosed in either
immature phagosomes or phagolysosomes [45] is a matter of debate.
EM observation of thin sections ﬁrst showed that NPs, with or without
MA, were not free in the macrophage cytosol. They all resided in
phagosomes of which the membrane was clearly visible, except for
the case of tangential sections through phagosomes for which it is
well known that membranes cannot be clearly seen. Evidence for classi-
fying phagosomes as being phagolysosomes or immature phagosomes
is based on the luminal presence or absence of electron-dense markersndex Zeta potential (mV) INH and MA loading (w/w)
−22.9 (±6.3) INH: 2%
−23.3 (±5.2) INH: 4%
MA: 2%
−21.3 (±5.8) INH: 3%
−21.4 (±4.9) INH: 5%
MA: 2%
Fig. 1.Morphological appearance of large or small NPs without or with MA incorporated into the PLGA shell. Freeze dried particles, recovered after encapsulation of INH and MA by the
double emulsion evaporation technique, were processed for SEM. A) large PLGA particles; B) large PLGA/MA particles; C) small PLGA particles; and D) small PLGA/MA particles. The vast
majority of particles are spherical and display a smooth surface. Bars in all panels, 0.5 μm. E) Ability of suspended large and small PLGA/MA particles to inhibit TB patient serum antibody
binding to immobilizedMA inELISA. No signiﬁcant inhibitionwasdetectedusing a healthy human control serum. The error bars indicate the standarddeviation (n=3). Both the large and
small MA containing particles are statistically signiﬁcantly different from particles without MA (p = 0.05).
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(Fig. 3A, B, C), or simply based on their electron-dense lysosomal con-
tents (Fig. 3D, E, F) (see e.g., de Chastellier et al., 2009 [54]). To this
aim, uninfected cells or cells infected withM. bovis BCG were exposed
to BSA-Au chased to lysosomes prior to phagocytic uptake of PLGA or
PLGA/MA particles. NP-containing phagosomes were observed under
the EM for the presence or absence of the lysosomal marker BSA-Au
during uptake of NPs (0–4 h uptake). Three different categories of
phagosomes were encountered: i) BSA-Au-negative phagosomes con-
taining a single NP. These phagosomes were often surrounded by
many BSA-Au-positive lysosomes (Fig. 3A); ii) BSA-Au-positive
phagosomes containing a single NP (Fig. 3B) and, iii) BSA-Au-positive
phagosomes containing two or more NPs (Fig. 3C). The ﬁrst category
corresponds to an immature phagosomewhile the two other categories
correspond to phagolysosomes that have acquired lysosomal material
following their fusion with lysosomes.
NP-containing phagosomeswere then scored for the presence or ab-
sence of BSA-Au. For both types of NPs, 90 to 100% of the phagosomes
containing 2 or more NPs were processed into BSA-Au positive
phagolysosomes within a 1-h exposure. In the case of phagosomes con-
taining only one NP, phagosome processing into phagolysosomes wasslower. Forty percent of the PLGA/MA-containing phagosomes vs 25%
of those containing PLGA NPs also contained the lysosomal marker
after a 1-h exposure. This percentage increased with the exposure
time in such a way that by 4 h about 78% of the phagosomes with a sin-
gle NP were BSA-Au positive, qualifying them as phagolysosomes.
Due to the rapid excretion of BSA-Au from BMDM lysosomes (see,
e.g. de Chastellier et al., 2006 [27]), it was not possible to use thismarker
during the chase period. We therefore screened for the presence or ab-
sence of the naturally dense lysosomal material which is typical and
easy to visualize in BMDM lysosomes and phagolysosomes (see e.g. de
Chastellier et al., 2006 [27]). Cells either uninfected or infected with
M. avium,M. bovis BCG orMtbwere exposed to PLGA or PLGA/MA par-
ticles for 2 h. Cells were washed and re-fedwith NP-freemedium for up
to 9 days. At selected time points during the chase period, NP-
containing phagosomes were observed and scored for the presence or
absence of dense lysosomal material. Qualitative aspects of NP-
containing phagosomes that were positive for dense lysosomal material
are shown (Fig. 3D, E, F). Throughout the chase period, 90% of the
phagosomes containing either one or more NPs of either type displayed
dense lysosomal material and could therefore be classiﬁed as being
phagolysosomes.
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Fig. 2. Inclusion ofMA into the PLGA shell enhances phagocytic uptake of particles. BMDM
were infected withMtb. At day 6 p.i., cells were exposed to either PLGA NPs or PLGA/MA
NPs for 2 h, ﬁxed and processed for TEM. A, B) General views of cell proﬁles exposed to
PLGA NPs (A) or PLGA/MA NPs (B). NPs displayed a similar ultrastructure but were
more abundant when MA was incorporated in the PLGA shell. C) Quantitative evaluation
of the amount of NPs per cell proﬁle at the same time point. The values shown are accurate
to about+/−12% based on the evaluation of 60 to 100 cell proﬁles. Ly, lysosomes. Bars in
panels A and B: 1 μm.
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Mtb treatments make use of free drugs that may be partially or totally
degraded as they progress towards the site of infection. Consequently,
higher doses and/or longer treatments have been used to avoid transfer
of low doses that may induce drug resistance. Nano-encapsulation of
ﬁrst line drugs such as INH is an interesting alternative for circumventing
the negative effects of long treatments and/or high doses provided that
the polymers used for drug encapsulation resist degradation during pro-
gression towards infected cells and are only progressively degraded to de-
liver the drugs after their internalisation by target cells.
To test NP alteration/degradation and/or secretion from host cells,
infected BMDM exposed to PLGA or PLGA/MA particles for 2 h werewashed and re-fed with medium devoid of NPs for a period of 0 to
9 days. At selected time points, cells were ﬁxed and processed for EM.
NPs were ﬁrst examined for eventual alterations in shape and size. It
is important to note that on thin sections observed under the transmis-
sion electron microscope, NPs often display an ellipsoid shape rather
than the spherical shape as observed by SEM. This is due to unavoidable
sectioning constraints and is not a sign of degradation. At the outset of
the chase period, the vast majority of NPs had smooth surfaces
(Fig. 4A). During the chase period, blebs appeared on a small fraction
of both NP populations (Fig. 4B) and towards the late time points
much smaller NPs were found in phagolysosomes (Fig. 4C). A quantita-
tive evaluation of the particle size was performed over a 0 to 5-day
chase period. No signiﬁcant size decrease was observed for PLGA parti-
cles. In contrast the size of PLGA/MA particles decreased by 25%. This
might be due to the slight amphiphilic nature of MA, which could play
the role of additional surfactant that facilitates faster degradation of
the NP and loss of MA from the NP surface although one cannot exclude
that PLGA might also be damaged by lysosomal enzymes and pH. The
percentage of NP-positive cell proﬁles as well as the average amount
of NPs per cell proﬁle was also assessed during the same period of
chase. For both PLGA and PLGA/MA, the percentage of NP-positive
cells (Fig. 4D) as well as the amount of NPs per cell proﬁle (Fig. 4E)
started to decline after 2 days of chase. After 5 days of chase, the mean
number of NPs per cell proﬁle remained higher in cells exposed to
PLGA/MA than in those exposed to PLGA particles (3.6 and 0.7, respec-
tively), and for both cases, macrophages still contained NPs after a 9-
day period of chase (data not shown).
3.5. NPs are targeted to mycobacterium-containing phagolysosomes
We then determined whether PLGA or PLGA/MA NPs reached
endomembrane compartments already harbouring different strains of
mycobacteria. For this,M. avium orM. bovis BCG-infected cells were in-
cubated with the NPs that were chased for 0 to 9 days. As expected, NPs
were not encountered in phagosomes containing a single mycobacteri-
um and devoid of dense lysosomal material, which correspond to non-
matured phagosomes. In contrast, both large and small NPs, with or
without MA, were found in some phagolysosomes containing either
one or several mycobacteria (Fig. 5A, B, C, D). With the large particles,
co-localisation of NPs and mycobacteria occurred starting from day 5
of chase and with a higher frequency when MA had been included in
the PLGA polymer. Interestingly, the small NPs were delivered to
mycobacterium-containing phagolysosomes much sooner, starting
from day 1 of chase.
4. Discussion
The aim of the present work was to design a novel nanoformulation
with targeting ligands that would improve efﬁcacy of anti-TB drug de-
livery. Addition of targeting ligands to the surface of nano drug delivery
vehicles have been shown to have beneﬁcial properties such as lower-
ing dosages required and reducing toxic side-effects [7]. Targeting
ligands thatwere studied to date include sugars (for instancemannose),
proteins (for example antigens such as peptides), nucleic acid aptamers
and antibodies [55–60]. In a fresh approach, we incorporated mycobac-
terial cell wall MA, a highly hydrophobic molecule, as a targeting ligand
into a drug-encapsulating PLGA polymer. MA is an attractive targeting
ligand for several reasons. Amongst all targeting candidate ligands con-
sidered to date, MA is by far the most robust and stable. This highly hy-
drophobic molecule could indeed be detected intact in 9000 year old
mummiﬁed corpses of humanswho succumbed to TB [61]. Another im-
portant feature of MA is that it is a major virulence factor of pathogenic
mycobacteria [19].
Our results showed that the mere inclusion of MA as reagent in the
preparation of drug loaded PLGA particles caused them to be exposed
on the outer surface of PLGA/MA particles. We also observed a strong
Fig. 3. The preferred residence of PLGA and PLGA/MA particles is a phagolysosome. A, B, C) BMDMwere infectedwithM. bovis BCG. At day 6 p.i., cells were exposed to BSA-Auwhichwas
chased to lysosomes prior to phagocytic uptake of large PLGA or PLGA/MA particles. A) 2 hr uptake of PLGA NPs. BSA-Au — positive lysosomes (Ly) are located in the close vicinity of a
phagosome containing a single NP and no gold particles; B) 2 hr uptake of PLGA/MA. A BSA-Au-positive Ly is fusing (arrowheads)with a phagosome containing a single NP; C) 2 hr uptake
of PLGA/MA. This phagosome contains 2 NPs and BSA-Au (arrow), indicating that it has fusedwith Ly. D, E, F) BMDMwere infected withM. bovis BCG. Six days later cells were exposed to
NPs, ﬁxed and processed for EM. D) 4 hr uptake of large PLGA NPs. The phagosomewhich contains a single NP is fusing with (arrowheads) a Ly ﬁlled with densematerial (arrow); E) 4 hr
uptake of large PLGA/MA. This phagosome which contains several NPs is ﬁlled with dense Ly material (arrow); F) 2 hr uptake of small PLGA/MA followed by a 24-hr chase into NP-free
medium. This phagosome which contains several NPs is ﬁlled with dense Ly material (arrow). Bars in panels A to F), 0.5 μm.
100 Y. Lemmer et al. / Journal of Controlled Release 211 (2015) 94–104and signiﬁcant increase in phagocytic uptake of MA coated NP by
mycobacterium-infected macrophages. The facilitation of phagocytic
uptake might be best explained by binding of MA-coated NP to cell sur-
face receptors, such as scavenger receptors, involved in phagocytic up-
take ofMtb [62].
Our data also suggest that tuberculous mycobacterial derived MA
can act as anti-TB drug targeting ligand, according to a mechanism of
pathogen mimicry. The cholesteroid nature of MA and its ability tobind cholesterol [21] could not only serve as a ligand for cholesterol-
rich lipid-raft-like areas on infected cells, or more general cholesterol-
rich surfaces associated with granulomas, but may have transformed
the NPs to mimic oxidised low density lipoproteins that could be
taken up from circulation bymacrophages through scavenger receptors.
A major consequence of the enhanced phagocytic uptake of NPs coated
withMA is that this could in turn lead to amuch improved delivery rate
and concentration of active drug into the infected cells.
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Fig. 4.Degradation/loss of NPs engulfed by BMDM is a slow process. BMDM infectedwithM. tuberculosis orM. bovis BCGwere exposed to 800 nm-diameter PLGA or PLGA/MA particles for
2 h and then re-fed with particle-free medium for 0 to 5 days. At selected time points, cells were ﬁxed and processed for TEM. A, B, C) Three major types of particles were seen under the
TEM, viz. normal-sized NPs with a smooth surface (A), or with small blebs (arrows) at their surface (B), or NPs for which a signiﬁcant size decrease was observed (C). D, E) Quantitative
evaluation of the percentage of NP-containing cell proﬁles (D), and of the amount of NPs per cell proﬁle at the same time points. The inserts indicate the number of particles per class of NP
intensity (E). The values shown are accurate to about +/−12% based on the evaluation of 60 to 100 cell proﬁles. Bars in panels A, B, C), 0.5 μm.
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ﬁning the fate of NPs after phagocytic uptake by infected macrophages.
Among the different possibilities, localisation in endomembrane com-
partments, and more especially in phagolysosomes seemed to us the
most appropriate. We have, therefore re-investigated this issue with
EM approaches. It is important to recall that EM is the only technique
that can combine sensitive protein detection methods with detailed in-
formation on the ultrastructure of cellular compartments. Contrary to
recent information [63], NPs can be easily visualised under the EM pro-
vided that the appropriate solvent is used for dehydration steps. We
ﬁrst labelled lysosomes by exposing BMDM to BSA-Au that was chasedto lysosomes prior to addition of NPs. At later time points, when BSA-Au
had been secreted by macrophages, lysosomes were identiﬁed by the
presence of electron dense lysosomal material. We concluded that
both the MA decorated and non-decorated NPs were localised within
phagolysosomes within a few hours after their uptake by macrophages
and that they remained in this compartment for at least 9 days. Similarly
our small and larger sized non-decorated PLGA NPs resided in the
phagolysosomes for up to 9 days in primary murine macrophage cells.
Our data deﬁnitely put an end to contrasting data presented in the liter-
ature for the localisation of unmodiﬁed PLGA particles in cells. Panyam
et al. reported that differently prepared PLGA particles were able to
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Fig. 5. Both PLGA and PLGA/MA, either large or small, are transferred to mycobacterium-containing phagolysosomes. BMDM infected with either M. bovis BCG (A, C, D) or M. avium
(B) were exposed to PLGA or PLGA/MA for 4 h. At selected time points between 0 and 9 days of chase in NP-free medium, cells were ﬁxed and processed for EM. Thin sections were ob-
served for the presence of NPs within mycobacterium-containing phagosomes. A) exposure to large PLGA NPs, chase for 5 days; B) exposure to large PLGA/MA, chase for 9 days;
C) exposure to small PLGANPs, chase for 6 days; D) exposure to small PLGA/MA, chase for 6 days. In all cases,NPswere found inphagolysosomes containing at least 2mycobacteria. Arrows
point to the phagosome membrane. Bars in panels A, B, C, D), 0.5 μm.
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colleagues in 2013, indicated by means of various techniques, that at
least 90% of PLGA particles remained in phagolysosomes after in vitro
uptake in BMDM cultures [45].
Clear proof of colocalisation of NPs and mycobacteria in the same
macrophages has been recently reported in the zebraﬁsh model [63]
but, not of colocalisation in the same cellular compartment. At ﬁrst
glance, this may seem logical, because the vast majority of NPs were
found to locate to phagolysosomes, while pathogenic mycobacteria re-
side and replicate in phagosomes that they prevent from maturing
and, as a result, from fusing with lysosomes or phagolysosomes
(reviewed in, e.g. de Chastellier, 2009 [34,54]). However, mycobacteria
prevent phagosomematuration only when they establish andmaintain
a close apposition with the phagosome membrane, a phenomenon
typically observed with single mycobacterial cell occupation of
phagosomes. Whenever several mycobacteria are enclosed in the
same phagosome — a frequent event in the case of M. bovis BCG or
Mtb, such phagosomes mature and fuse with lysosomes (reviewed in,
e.g., de Chastellier, 2009 [54]). Phagolysosomeswithmultiplemycobac-
terial occupation would then also be able to fuse with NP-containing
phagolysosomes. As a consequence one may therefore anticipate co-
localisation of NPs andmycobacteria. It is important to conﬁrm this, be-
cause depending on experimental conditions, such NP-containing
phagolysosomes may contain up to 50% or more of the mycobacterial
population phagocytosed by macrophages. Our current study gives the
ﬁrst clear proof of drug loaded NPs becoming enclosed within the same
phagosomal compartment as the infecting mycobacteria. For both the
large and the small NPs, with or without the MA, incidents of co-
localisation were observed, but at a higher frequency when MA hadbeen included in the PLGA polymer. Such phagosomes always contained
dense lysosomal material, conﬁrming them to be phagolysosomes. The
smallerNPswere found to co-localise quicker than the larger particles did.
Onemajor question that arises is whether the drug-loaded NPs have
an effect on M. tuberculosis or BCG growth and/or degradation. In our
previous study [48] human macrophage like cell lines were exposed to
MA liganded/unliganded, INH loaded particles for up to two days to
conﬁrm antibiotic efﬁcacy. At ﬁve hours of incubation, the results of
drug efﬁcacy were still found to be variable, but after one or two days
of exposure the inhibitory effect of INH was clearly conﬁrmed, also
when delivered from MA liganded nanoparticles. In the present study,
BMDM cells were exposed toMA liganded/unliganded, INH loaded par-
ticles for only two hours, after which the cells were washed and main-
tained in particle free medium before ﬁxation for EM analysis. This
prevented us from observing the efﬁcacy of intracellular INH release,
more especially as the particles were shown to degrade very slowly
over timewhich could assist in the slow release of the drug. This corrob-
orated the report by Tracy et al. on in vitro studies done with PLGA mi-
crospheres [64], reviewed by Fredenberg in 2011 [65]. The active INH
content of the NPs could in future be adjusted to an effective concentra-
tion that takes into consideration both the slow drug releasing nature of
the PLGA particle and the degree of targetting achievable by the MA
ligandation. The concentrations of INH in the particles used for the EM
observations were approximately 5 μg/ml in the preparation medium,
ten times less than a recent in vitro study of an INH analogue that was
tested in PLGA particles [47]. As mentioned before, INH-PLGA NPs
have shown sustained drug release over several days in vitro and
in vivo [66] and allowed a reduction in treatment frequency in mice
and guinea pigmodels [67–69]. Most chemotherapeutic efﬁcacy studies
103Y. Lemmer et al. / Journal of Controlled Release 211 (2015) 94–104in TB on these types of formulations are conducted in vivo, and will be
addressed in future work. The in vitro BMDM approach tested here al-
lows better understanding of why targeted anti-TB nanomedicine may
work better in vivo.
We propose that the MA-decorated PLGA-based targeted nano-
therapeutic,which arguably could be applied both as an inhaled product
or an oral formulation, will improve drug delivery at sites of infection to
ensure a high localised release of drug, while maintaining low blood
levels; thus with minimal toxic side-effects of the drugs. It was previ-
ously reported that MA-liganded PLGA particles, intradermally injected
into rabbits, caused no measurable degree of inﬂammation, compared
to a Freund's Incomplete Adjuvant control [70]. Combined with a
lower dose frequency, this may facilitate themanagement of the Direct-
ly Observed Treatment (DOTs) programme for TB therapy recommend-
ed byWHO for global TB control, This is especially relevant for patients
with drug resistant TB [71].
With multi- and extensively-drug resistant TB (MDR/XDR-TB)
consuming most of the ﬁnancial resources expended on TB in sub-
Saharan Africa [72], the scope provided by the positive indication of
MA as targeting ligand for anti-TB nanodrugs may provide timeous
hope for a positive solution to a serious current global health threat.
These potentially powerful beneﬁts of the targeted nanodrugs could
therefore best be trialled in multi-drug resistant TB patients where the
issue of toxicity of second line antibiotics treatment is especially
prominent.
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